Societe Generale recent bets

Morgan Stanley recent bets

Recent Big Buys

Top deal-making stocks

Most insider traded stocks

Leading investors

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Showing good signs of profitability & efficiency

Profitability

The stock is overpriced but is not in the overbought zone

Current price is more than the intrinsic value

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Hasn't fared well - amongst the low performers

Financials growth has been moderate for a few years

The stock is underpriced and is not in the overbought zone

Current price is less than the intrinsic value

The stock has a moderate number of red flags

The creamy layer - amongst the top performing stocks

Strong financials and growth story over the years

Average profitability - not good, not bad

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

GSK@100: Reinvention and resilience critical to its journey, says MD

The Nifty Pharma index closed 0.86 per cent at 22151.60.

Stock market update: Nifty Pharma index 0.86%

In this interview with ETMarkets, Gautam Chhaochharia, Head of Global Markets, India at UBS, shares UBS’s nuanced outlook on the Indian market amidst ongoing global and domestic challenges.Despite recent corrections, he notes that valuations remain high, particularly in the small-cap space.UBS favors sectors like Utilities and Industrials, while adopting a cautious stance on Autos, Consumer Discretionary, and selective Financials and Pharma stocks due to specific growth and valuation concerns.India’s valuations, rich in comparison to other emerging markets (EMs), lead UBS to maintain an underweight position on Indian equities in the near term, even as long-term growth prospects remain strong. Edited Excerpts - UBS on Indian markets, top sectors to watch out for

UBS recommends caution on mid and small cap stocks; remains underweight on India - UBS on Indian markets, top sectors to watch out for

The Nifty Pharma index was trading 0.61 per cent at 22480.60.

Stock market update: Nifty Pharma index 0.61% in an upbeat market

The Nifty Pharma index closed 0.88 per cent at 22344.25.

Stock market update: Nifty Pharma index 0.88%

The Nifty Pharma index closed 0.07 per cent at 22542.25.

Stock market update: Nifty Pharma index 0.07%

The Nifty Pharma index was trading 0.12 per cent at 22554.80.

Stock market update: Nifty Pharma index 0.12% in a weak market

Stay updated with the Sun Pharma Stock Liveblog, your one-stop destination for real-time information and analysis of a leading stock. Explore the latest updates on Sun Pharma stock, including: Last traded price 1799.8, Market capitalization: 429708.9, Volume: 1977, Price-to-earnings ratio 38.87, Earnings per share 46.07. Our liveblog combines fundamental and technical insights to offer a comprehensive overview of Sun Pharma’s performance. Gain valuable market knowledge and make informed decisions with our expert analysis. Be the first to know about breaking news that can impact Sun Pharma’s trajectory. Join us on this journey as we explore the exciting potential of Sun Pharma. The data points are updated as on 08-11-2024 09:11 IST

Sun Pharma Stocks: Sun Pharma closes at Rs 1790.95 - The Economic Times

​Across the whole pharma sector, there are four or five stocks big one out there which are going to gain market share. So, CDMO is one space within pharma which should do well as we go along. But pharma as a whole space per se has been doing okay and we continue to believe that incrementally also pharma should continue to do well in the coming year also.

Why four-wheelers stocks are still facing headwinds? Nischal Maheshwari answers

Telangana’s pharmaceutical industry faces challenges with rising accidents, emphasizing the need for fire safety and technology solutions.

Telangana pharmaceutical industries logged 97 major fire accidents in past decade: Fire Services Director-General Y. Nagi Reddy

Stay up-to-date with the Sun Pharma Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a prominent stock. Explore the latest information on Sun Pharma, including: Last traded price 1845.0, Market capitalization: 438466.47, Volume: 11875, Price-to-earnings ratio 39.67, Earnings per share 46.07. Our liveblog provides a comprehensive overview of Sun Pharma by integrating fundamental and technical indicators. Stay informed about breaking news that can impact Sun Pharma’s performance in the market. Our expert analysis and stock recommendations empower you to make well-informed financial decisions. Join us on this journey as we delve into the exciting world of Sun Pharma and its market potential. The data points are updated as on 07-11-2024 09:10 IST

Sun Pharma Stocks: Sun Pharma’s Stock Price Movement - The Economic Times

The ETF tracks Nifty Pharma Index which is designed to reflect the behavior and performance of the pharmaceutical sector in India.